Fig 2.

Association between viral load (VL) and CD4⁺ T-cell counts prognostic markers and HLA-B*81:01 and HLA-B*39:10 alleles at 12 and 36 months postinfection. (A and C) Log₁₀ VL values compared between individuals without and with HLA-B*81:01, HLA-B*39:10, or HLA-B*57:03/58:01 alleles at 12 and 36 months postinfection; (B and D) CD4⁺ T-cell counts compared between individuals without and with HLA-B*81:01, HLA-B*39:10, or HLA-B*57/58:01 alleles at 12 and 36 months postinfection, respectively. B*81:01-positive participants shown as empty symbols are those positive for the Cw*04:01 allele. Both B*39:10-positive participants are also positive for the Cw*12:03 allele. Viral load and CD4⁺ T-cell counts were calculated as medians of measurements taken at three time points closest to these intervals. To not enrich for slow progressors, we included the last attained median values for viral load and CD4⁺ T-cell counts before the initiation of ARV therapy for individuals who had received treatment prior to 12 months (n = 7) or 36 months (n = 12) postinfection.